Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
MBIO 
Mustang Bio Inc (MBIO)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/10/2025: MBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -43.02% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.11M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 14367721 | Beta 1.92 | 52 Weeks Range 0.13 - 1.52 | Updated Date 01/14/2025 |
52 Weeks Range 0.13 - 1.52 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.33 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -96.52% | Return on Equity (TTM) -1191.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8566629 | Price to Sales(TTM) - |
Enterprise Value 8566629 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 48768900 | Shares Floating 43285082 |
Shares Outstanding 48768900 | Shares Floating 43285082 | ||
Percent Insiders 15.68 | Percent Institutions 5.72 |
AI Summary
Mustang Bio Inc.: A Comprehensive Overview
Company Profile:
History and Background: Mustang Bio Inc. (NASDAQ: MBIO) is a clinical-stage biopharmaceutical company established in 2013. They specialize in developing innovative T-cell receptor (TCR) and CAR T immunotherapies to treat various cancers and autoimmune diseases.
Core Business Areas: Mustang Bio focuses on three primary business areas:
- TCR-T Therapies: These therapies use engineered T cells designed to recognize and kill tumor cells with specific mutations.
- CAR-T Therapies: These therapies involve modifying T cells to recognize and attack tumor cells with a specific antigen.
- Autoimmune Disease Therapies: Mustang Bio is exploring the application of its TCR-T platform for autoimmune diseases.
Leadership and Corporate Structure: Mustang Bio's leadership team comprises experienced professionals with expertise in biotechnology, medicine, and business development. Their board of directors includes individuals with extensive experience in the healthcare industry.
Top Products and Market Share:
- MB-101: This TCR-T therapy targets tumors with NKG2D ligands. It is currently in Phase I/II clinical trials for the treatment of advanced/metastatic colorectal cancer.
- MB-102: This CAR-T therapy targets MUC16. It is currently in Phase I clinical trials for the treatment of ovarian cancer.
Mustang Bio does not currently have any marketed products, and therefore, no market share data is available.
Total Addressable Market: The global T-cell therapy market is expected to reach USD 21.89 billion by 2028, growing at a CAGR of 19.1%. The CAR-T therapy market is estimated to reach USD 14.07 billion by 2027, with a CAGR of 24.9%.
Financial Performance:
Mustang Bio is a clinical-stage company without any marketed products yet. Therefore, its revenue is primarily generated from collaboration agreements and research grants. The company has reported net losses in recent years due to significant research and development expenses.
Dividends and Shareholder Returns:
Mustang Bio does not currently pay dividends as it is focused on reinvesting its resources for future growth. The company's shareholder returns have been negative in recent years due to its development stage and lack of profitability.
Growth Trajectory:
Mustang Bio has experienced rapid growth in recent years, driven by its promising pipeline of TCR-T and CAR-T therapies. The company plans to advance its lead candidates, MB-101 and MB-102, through clinical development and potentially seek regulatory approvals in the coming years.
Market Dynamics:
The T-cell therapy market is characterized by strong growth potential due to the increasing adoption of personalized medicine and the development of novel therapies with improved efficacy and safety profiles. However, the market is also highly competitive, with several established players and numerous emerging companies vying for market share.
Competitors:
Key competitors in the T-cell therapy market include:
- Kite Pharma (NASDAQ: KITE)
- Novartis (NYSE: NVS)
- Gilead Sciences (NASDAQ: GILD)
- Bristol Myers Squibb (NYSE: BMY)
- Celgene (NASDAQ: CELG)
Potential Challenges and Opportunities:
Challenges:
- Competition: Mustang Bio faces intense competition from established players in the T-cell therapy market.
- Clinical Development Risks: The development of TCR-T and CAR-T therapies is associated with significant clinical risks and uncertainties.
- Regulatory Approval: Obtaining regulatory approval for new therapies can be a lengthy and complex process.
Opportunities:
- Growing Market: The T-cell therapy market is expected to experience strong growth in the coming years, offering significant market opportunities for Mustang Bio.
- Promising Pipeline: Mustang Bio's pipeline of TCR-T and CAR-T therapies includes several promising candidates with the potential to address significant unmet medical needs.
- Strategic Partnerships: Mustang Bio could leverage strategic partnerships with larger pharmaceutical companies to accelerate its development programs and commercialization efforts.
Recent Acquisitions:
Mustang Bio has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
Based on an AI-based analysis of Mustang Bio's fundamentals, the company receives a rating of 7 out of 10. This rating considers factors such as financial health, market position, and future growth prospects.
Justification:
Mustang Bio has a strong pipeline of promising T-cell therapies and operates in a high-growth market. However, the company's lack of profitability and intense competition from established players present significant challenges.
Sources:
- Mustang Bio Inc. website (https://www.mustangbio.com)
- Yahoo Finance (https://finance.yahoo.com/quote/MBIO/)
- Grand View Research (https://www.grandviewresearch.com/)
- Evaluate Vantage (https://www.evaluate.com/)
Disclaimer:
This information is intended for educational purposes only and should not be construed as financial advice. Investing in stocks involves significant risks, and investors should always conduct their own due diligence before making any investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Worcester, MA, United States | ||
IPO Launch date 2017-08-22 | President, CEO, Director & Interim CFO Dr. Manuel Litchman M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 80 | Website https://www.mustangbio.com |
Full time employees 80 | Website https://www.mustangbio.com | ||
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Avenue Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.